To compare the effect of four and a half days treatment of a range of doses of AZD5363 on
selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen
receptor positive breast cancers.
To assess the tolerability of four and a half days treatment of AZD5363.
Phase:
Phase 2
Details
Lead Sponsor:
University of Nottingham
Collaborators:
AstraZeneca Cancer Research UK National Cancer Research Network